May 2nd 2024
Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
What Is the Role of SCT as Novel Agents Emerge for Relapsed/Refractory HL?
November 19th 2018During a presentation at the National Comprehensive Cancer Network 13th Annual Conference: Hematologic Malignancies Phillippe Armand, MD, PhD, discusses how novel agents could be used in the future either to postpone, permit, or even replace allogeneic stem cell transplantation.
Read More
Small Molecule Inhibitors Prove Effective in Targeting NHL
November 17th 2018A greater understanding of molecular pathogenesis in non-Hodgkin lymphoma has led to the identification of rational targets for novel small molecule inhibitors, according to Andrew D. Zelenetz, MD, PhD. Combinations of these therapies may also provide greater responses and the potential for therapy discontinuation.
Read More
Brentuximab Vedotin Granted FDA Approval for Frontline CD30+ PTCL
November 16th 2018Brentuximab vedotin (Adcetris) has been granted FDA approval for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma, based on findings from the phase III ECHELON-2 trial.
Read More
Brentuximab Vedotin Submitted for FDA Approval in Frontline CD30+ PTCL
November 6th 2018Based on findings from the phase III ECHELON-2 trial, brentuximab vedotin (Adcetris) has been submitted to the FDA for approval in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma.
Read More
Emerging Treatment Strategies for Patients With MCL
November 1st 2018Simon Rule, MD, PhD, discusses the treatment options available for younger, fit patients with MCL, including the watch-and-wait approach and BTK inhibitors. He also highlights several clinical trials supporting these strategies, as well as other ongoing trials aiming to advance the treatment landscape for the older patient population.
Read More
New Regimens Lead to More Personalized Approach in Hodgkin Lymphoma, MCL
October 24th 2018The treatment landscapes of Hodgkin lymphoma and mantle cell lymphoma have progressed to a more personalized therapeutic approach in clinical practice due to the introduction of the latest novel regimens, according to Chaitra S. Ujjani, MD.
Read More
Experts Remark on CAR T-Cell Therapy at 1-Year Milestone, Where It Is Headed
October 19th 2018With 2 CAR T-cell therapies now approved and more moving quickly through early-phase clinical trials, 4 healthcare experts reflected on the evolving field of CAR T-cell therapy, their understanding of its current and future applicability for patients, the process for administration and the challenges and obstacles that remain unaddressed during an Association of Community Cancer Centers interactive panel.<br />
Read More
ODAC Recommends FDA Approval of Rituximab Biosimilar
October 10th 2018In a 16-0 vote, the FDA’s Oncologic Drugs Advisory Committee has recommended the approval of the rituximab biosimilar CT-P10 for 3 of the anti-CD20 monoclonal antibody’s non-Hodgkin lymphoma indications.
Read More
ILROG Guidelines Recommend Proton Therapy to Limit Damage to OARs in Mediastinal Lymphomas
October 10th 2018Guidelines from the International Lymphoma Radiation Oncology Group recommend the use of proton therapy in adults with mediastinal lymphomas and for young women. Specifically, clinicians should consider proton therapy in mediastinal disease that spans below the left main stem coronary artery and is near the front of, behind, or on the left side of the heart.
Read More
Lenalidomide/Rituxumab Combo Maintains Durable Responses at 5 Years in MCL
October 4th 2018Patients with mantle cell lymphoma who were treated with the combination of lenalidomide (Revlimid) and rituximab (Rituxan) continued to have durable responses and manageable side effects at 5 years of follow-up.
Read More
Survival Improvement Seen With Frontline Brentuximab Vedotin in CD30+ PTCL
October 2nd 2018Patients with CD30-expressing peripheral T-cell lymphoma who were treated with the combination of brentuximab vedotin and frontline chemotherapy experienced a statistically significant improvement in progression-free and overall survival, according to topline results from the phase III ECHELON-2 trial.
Read More
Pontchartrain Cancer Center Pushes Limits of Community Care in Southeast Louisiana
September 27th 2018Pontchartrain Cancer Center was founded in 2005 to serve an area of Louisiana that lacked the necessary resources for cancer care. This community cancer center, with 2 locations in Southeast Louisiana, accommodates any patient to walk through its doors, filling a major unmet need for the community in this rural area.
Read More
Relapsed/Refractory MCL Landscape Continues to Evolve
September 15th 2018Mantle cell lymphoma remains an incurable disease, but according to Michael Wang, MD, it is becoming one of the most dynamic fields in oncology. In a presentation during the 2018 SOHO Annual Meeting, Wang recapped some of the biggest advancements in relapsed/refractory MCL, as well as the promise for novel therapies in this setting.
Read More
BTK Inhibitors Will Make Significant Impact in MCL, Expert Says
September 7th 2018In an interview with <em>Targeted Oncology</em>, Simon Rule, MD, PhD, professor of Hematology at Plymouth University Medical School, United Kingdom, discusses the current treatment paradigm for MCL, as well as the potential use of BTK inhibitors for the treatment of this patient population.
Read More
Recent Advances in Mantle Cell Lymphoma
September 6th 2018Jacqueline D. Barrientos, MD, MS, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the most recent advances in mantle cell lymphoma, as well as the challenges investigators still face in the field.
Watch
Axicabtagene Ciloleucel Gains Approval in Europe for DLBCL, PMBCL
August 28th 2018Axicabtagene ciloleucel (axi-cel; Yescarta) has been approved by the European Commission as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma, following at least 2 lines of systemic therapy.
Read More
Tisagenlecleucel Granted Approval in Europe for DLBCL, ALL
August 27th 2018Tisagenlecleucel has gained approval from the European Commission as a treatment for adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.
Read More
TP53, WHSC1 Mutations Key to MCL Prognosis
August 22nd 2018Mutations of <em>TP53</em> and <em>WHSC1 </em>predicted poorer overall survival in patients with mantle cell lymphoma, according to results from next-generation whole-exome sequencing of 16 Chinese patients. The presence of these mutations may provide physicians with an important biomarker in this patient population.
Read More
Targeting EZH2 Delivers Promising Activity in Lymphomas
August 17th 2018Targeting EZH2, the catalytic subunit of the multiprotein PRC2, may represent an attractive therapeutic objective in malignant lymphoma, Vincent Ribrag, MD, told his audience at the American Association for Cancer Research’s inaugural Advances in Malignant Lymphoma meeting.
Read More